IKT
Inhibikase Therapeutics Inc
2.30$
-0.4%
vs. previous close
Closing price · As of: Sep 17, 2026
Filings
Filings
Listed US companies must report material events to the Securities and Exchange Commission. This page lists the filings of Inhibikase Therapeutics Inc (IKT) with date, type and a link to the original document.
| Date | Type | Filing | Original |
|---|---|---|---|
| 09/08/2026 | Current report (8-K) | Inhibikase Therapeutics, Inc. (IKT): Regulation FD Disclosure; Financial Statements and Exhibits | View report ↗ |
| 08/26/2026 | Current report (8-K) | Inhibikase Therapeutics, Inc. (IKT): Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View report ↗ |
| 08/11/2026 | Current report (8-K) | Inhibikase Therapeutics, Inc. (IKT): Results of Operations and Financial Condition; Financial Statements and Exhibits | View report ↗ |
| 07/29/2026 | Current report (8-K) | Inhibikase Therapeutics, Inc. (IKT): Unregistered Sales of Equity Securities; Financial Statements and Exhibits | View report ↗ |
| 07/28/2026 | Ownership disclosure | Form SC 13G filed with the SEC | View document ↗ |
| 07/23/2026 | Current report (8-K) | Inhibikase Therapeutics, Inc. (IKT): Regulation FD Disclosure; Financial Statements and Exhibits | View report ↗ |
| 07/17/2026 | Ownership disclosure | Form SC 13G filed with the SEC | View document ↗ |
| 07/14/2026 | Current report (8-K) | Inhibikase Therapeutics, Inc. (IKT): Other Events; Financial Statements and Exhibits | View report ↗ |
Showing the 100 most recent filings of the selected type.
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Filings: SEC EDGAR
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.